Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219238 | 0.74 | RECQL (0.37) | MAPK1KMT2ARECQLBACE1CTSD | |
| SCHEMBL18532580 | 0.64 | NOS2 (0.31) | — | |
| SCHEMBL8204734 | 0.62 | LMNA (0.42) | MAPK1KMT2ARECQLLMNA | |
| SCHEMBL4238234 | 0.59 | BACE1 (0.68) | MAPK1KMT2ARECQLBACE1CTSD | |
| SCHEMBL10154529 | 0.57 | BACE1 (0.49) | BACE1 | |
| SCHEMBL3610038 | 0.57 | TAAR1 (0.71) | — | |
| SCHEMBL3610035 | 0.57 | TAAR1 (0.71) | — | |
| SCHEMBL7099930 | 0.56 | LMNA (0.51) | MAPK1KMT2ARECQLLMNA | |
| SCHEMBL542817 | 0.56 | LMNA (0.51) | MAPK1KMT2ARECQLLMNA | |
| SCHEMBL4280081 | 0.56 | CYP1A2 (0.37) | KMT2ABACE1CTSDBACE2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608369-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | claimed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| EP-1608369-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2258365-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2583678-A2 | Small molecule immunopotentiators and assays for their detection | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2258365-A1 | Use of organic compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | ICOS, CD14, LCP2 | MAPK1 2449/4885KMT2A 2125/4885RECQL 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.